KU-57788 5 mg | 99.87%
TargetMol
NU7441 (KU-57788) is a highly effective and specific DNA-PK inhibitor (IC50: 14 nM).
More Information Supplier PageKU-57788
Search Results
KU-57788 50 mg | 99.87%
TargetMol
NU7441 (KU-57788) is a highly effective and specific DNA-PK inhibitor (IC50: 14 nM).
More Information Supplier PageKU-57788
Mirdametinib 10 mg | 99.91%
TargetMol
PD0325901 is a specific and non-ATP-competitive MEK inhibitor (IC50: 0.33 nM).
More Information Supplier PageMirdametinib
Mirdametinib 100 mg | 99.91%
TargetMol
PD0325901 is a specific and non-ATP-competitive MEK inhibitor (IC50: 0.33 nM).
More Information Supplier PageMirdametinib
Orantinib 5 mg | 100.00%
TargetMol
TSU-68, a excellent effective against PDGFR autophosphorylation with Ki of 8 nM, also highly inhibits Flk-1 and FGFR1 trans-phosphorylation. It shows little effect against IGF-1R, Met, Src, Lck, Zap70, Abl and CDK2 and does not suppresses EGFR.
More Information Supplier PageOrantinib
Orantinib 50 mg | 100.00%
TargetMol
TSU-68, a excellent effective against PDGFR autophosphorylation with Ki of 8 nM, also highly inhibits Flk-1 and FGFR1 trans-phosphorylation. It shows little effect against IGF-1R, Met, Src, Lck, Zap70, Abl and CDK2 and does not suppresses EGFR.
More Information Supplier PageOrantinib
Orantinib 25 mg | 100.00%
TargetMol
TSU-68, a excellent effective against PDGFR autophosphorylation with Ki of 8 nM, also highly inhibits Flk-1 and FGFR1 trans-phosphorylation. It shows little effect against IGF-1R, Met, Src, Lck, Zap70, Abl and CDK2 and does not suppresses EGFR.
More Information Supplier PageOrantinib
Orantinib 10 mg | 100.00%
TargetMol
TSU-68, a excellent effective against PDGFR autophosphorylation with Ki of 8 nM, also highly inhibits Flk-1 and FGFR1 trans-phosphorylation. It shows little effect against IGF-1R, Met, Src, Lck, Zap70, Abl and CDK2 and does not suppresses EGFR.
More Information Supplier PageOrantinib
MRS 2578 50 mg | Purity Not Available
TargetMol
MRS2578, an effective P2Y6 receptor antagonist with IC50 of 37 nM, shows insignificant inhibition at P2Y1, P2Y2, P2Y4, and P2Y11 receptors.
More Information Supplier PageMRS 2578
Mirdametinib 25 mg | 99.91%
TargetMol
PD0325901 is a specific and non-ATP-competitive MEK inhibitor (IC50: 0.33 nM).
More Information Supplier PageMirdametinib